ERBB2 and breast carcinoma: To this end, we reduced WDR5 in additional breast cancer lines spanning three established molecular subtypes: TNBC (MDA-MB-453 and HCC1143), estrogen receptor positive (MCF7, T47D, and MDA-MB-361), and HER2+ (UACC893, BT474, and SKBR3) (Figure 2A).